Innovative Trial for Understanding the Impact of Targeted Therapies in NF2
Status:
Recruiting
Trial end date:
2030-12-01
Target enrollment:
Participant gender:
Summary
This is a multi-arm phase II platform-basket screening study designed to test multiple
experimental therapies simultaneously in patients with neurofibromatosis type 2 (NF2) with
associated progressive tumors of vestibular schwannomas (VS), non-vestibular schwannomas
(non-VS), meningiomas, and ependymomas.
This Master Study is being conducted as a "basket" study that may allow people with multiple
tumor types associated with NF2 to receive new drugs throughout this study. Embedded within
the Master Study are individual drug substudies.
- Investigational Drug Sub-study A: Brigatinib